Page 70 - நரம்பியல் மருத்துவ ஆராய்ச்சி நிறுவனம் இல் மாசசூசெட்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நரம்பியல் மருத்துவ ஆராய்ச்சி நிறுவனம் இல் மாசசூசெட்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நரம்பியல் மருத்துவ ஆராய்ச்சி நிறுவனம் இல் மாசசூசெட்ஸ் Today - Breaking & Trending Today

People with and without AD have a different threshold for elective revascularisation


 E-Mail
The risk of both mortality and rehospitalisation after an elective revascularisation procedure for coronary artery disease is similar for people with and without Alzheimer s disease (AD), but people with AD had worse outcomes after an emergency procedure, according to a new study from the University of Eastern Finland.
Previous studies have investigated the effectiveness of revascularisation in persons with cognitive disorders, but only in terms of short-term outcomes and in acute care settings, and they also have not accounted for electivity. Similar to previous studies, people with Alzheimer s disease were 76% less likely to undergo a revascularisation procedure and only a third of the procedures were elective, compared to 48.6% of elective procedures in the comparison group without AD. ....

Raimo Kettunen , Marjaana Koponen , Sirpa Hartikainen , Heidi Taipale , Anna Maija Tolppanen , Mai Vu , Academy Research Fellow Anna Maija Tolppanen , Academy Of Finland , School Of Pharmacy , Schlumberger Foundation , University Of Eastern Finland , Medication Use , Disease Study , Medicine Health , Alzheimers Disease , மை உ , கலைக்கழகம் ஆஃப் பின்லாந்து , பள்ளி ஆஃப் மருந்தகம் , ஸ்க்லம்பர்ஜர் அடித்தளம் , பல்கலைக்கழகம் ஆஃப் கிழக்கு பின்லாந்து , மருந்து பயன்பாடு , நோய் படிப்பு , மருந்து ஆரோக்கியம் , அல்சைமர் நோய் , அறுவை சிகிச்சை ,

Differences in walking patterns could predict type of cognitive decline in older adults


 E-Mail
Canadian researchers are the first to study how different patterns in the way older adults walk could more accurately diagnose different types of dementia and identify Alzheimer s disease.
A new study by a Canadian research team, led by London researchers from Lawson Health Research Institute and Western University, evaluated the walking patterns and brain function of 500 participants currently enrolled in clinical trials. Their findings are published today in
Alzheimer s & Dementia: The Journal of the Alzheimer s Association.
We have longstanding evidence showing that cognitive problems, such as poor memory and executive dysfunction, can be predictors of dementia. Now, we re seeing that motor performance, specifically the way you walk, can help diagnose different types of neurodegenerative conditions, says Dr. Manuel Montero-Odasso, Scientist at Lawson and Professor at Western s Schulich School of Medicine & Dentistry. ....

City Of , United Kingdom , Frederico Perruccini Faria , Manuel Montero Odasso , Laura Goncalves , London Health Sciences Centre , Schulich School Of Medicine Dentistry , Journal Of The Alzheimer Association , Canadian Institutes Of Health Research , Joseph Health Care London , Canadian Consortium On Neurodegeneration , Research Assistant At Lawson , Lawson Health Research Institute , Western University , Schulich School , Subjective Cognitive Impairment , Mild Cognitive Impairment , Research Assistant , Postdoctoral Associate , Canadian Consortium , Canadian Institutes , External Relations , Health Research Institute , Health Care London , Western Experience , Medicine Health ,

Neuren Pharmaceuticals updates on phase one trial


Date Time
Neuren Pharmaceuticals updates on phase one trial
Australian biotechnology company Neuren Pharmaceuticals (ASX:NEU) has reported a phase one trial of its twice-daily oral investigative therapy NNZ-2591 found it was safe and well-tolerated for seven days.
The company said the data will form part of its planned Investigational New Drug (IND) application to the US FDA in preparation for phase two trials in Phelan McDermid, Angelman and Pitt Hopkins syndromes.
Neuren CEO Jon Pilcher said, “This trial was the first human dosing for NNZ-2591 and we are very pleased with the outcome. Twice daily oral dosing for seven days was safe and well-tolerated at doses we expect to be within the effective therapeutic range, which gives us confidence for dosing patients in our planned Phase 2 trials.” ....

Western Australia , New South Wales , Jon Pilcher , Phelan Mcdermid , Pitt Hopkins , Neuren Pharmaceuticals , Investigational New Drug , Serious Adverse Events , Biotechnology Industry , Clinical Trial , மேற்கு ஆஸ்திரேலியா , புதியது தெற்கு வேல்ஸ் , ஜான் பில்ச்சர் , ஃபெலன் மக்டர்மிட் , குழி ஹாப்கின்ஸ் , உயிரி தொழில்நுட்பவியல் , உயிரி தொழில்நுட்பவியல் தொழில் , மருத்துவ சோதனை ,